{
    "type": "ETP",
    "ucits": false,
    "replication_method": "synthetic",
    "leverage": true,
    "derivatives": true,
    "swaps": true,
    "inverse": true,
    "complex_factors": [
        "Leverage",
        "Inverse exposure",
        "Synthetic replication via swaps",
        "Daily leveraged compounding",
        "Counterparty risk",
        "High risk rating (7/7)",
        "Collateralised structure",
        "Complex index exposure"
    ],
    "classification": "complex",
    "supporting_data": "The product is a Collateralised Exchange Traded Security (ETP) providing -3x daily inverse exposure to the Solactive Magnificent 7 Index, indicating leverage and inverse exposure. The replication method is synthetic, as the underlying assets are held in a margin account including securities loans and collateral assets, implying use of swaps or derivative contracts. The document explicitly states the presence of stock borrow costs and margin accounts, consistent with synthetic replication and derivative usage. The product is not UCITS compliant, which often implies fewer regulatory constraints and potentially higher complexity. The risk indicator is at the highest level 7/7, reflecting very high risk and complexity. The product is intended for sophisticated investors with a very short holding period (1 day), highlighting the complexity of daily leveraged compounding and the compounding effect. The product lacks capital protection and has significant counterparty risk, as the issuer's payment obligations depend on liquidating collateral assets. The KIID warns that the product is 'not simple and may be difficult to understand,' and that holding beyond one day can lead to returns diverging significantly from the expected -3x multiple due to compounding effects. There is no capital guarantee or principal protection, and the product is exposed to currency risk and liquidity risk. Costs include management fees and transaction costs related to underlying derivative transactions. The product's structure, leverage, inverse exposure, synthetic replication, and high risk profile all point to a classification as complex under MiFID II rules."
}